PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Premera Blue CrossCommercial · Coverage · Medical Policy · WA · Orthopedics, Pain Management, ENT (Ear, Nose & Throat) +7 moreMedium impact

Medical Policy and Coding Updates - December 2023

Effective date
Not stated in the notice
Identified
Jun 18, 2026

Summary

Effective March 17, 2024, Carelon Medical Benefits Management Genetic Testing Clinical Appropriateness Guidelines (formerly AIM Specialty Health) replaced contraindicated with unsafe or infeasible for tissue biopsy in cell-free DNA testing, restricted somatic tumor testing to 50 genes or less for several cancers and leukemias, and removed the Afirma standalone assay for indeterminate thyroid nodules. Effective December 1, 2023, the Whole Body Dual X-Ray Absorptiometry and Bioelectrical Impedance Analysis to Determine Body Composition policy (6.01.528) states that whole-body dual energy X-ray absorptiometry or bioelectrical impedance analysis for body composition studies is investigational for all indications. Effective December 1, 2023, Premera HMO specified that inpatient mental health medical evaluations must be done by a physician, nurse practitioner, or physician assistant, or be done in an emergency department or hospital inpatient medical unit before direct transfer to the inpatient facility.

Get alerts when payers change rules like this one

We check Premera Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Premera Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 6 steps
01Already effective December 1, 2023: Codes 20560 and 20561 for dry needling of trigger points for myofascial pain now require review for investigational status.
02Already effective December 1, 2023: Code 0358T for whole body dual energy X-ray absorptiometry now requires review for investigational status.
03Already effective December 1, 2023: Dry needling of trigger points for the treatment of myofascial pain is investigational.
04Already effective December 1, 2023: Whole body DXA and bioelectrical impedance body composition studies are investigational for all indications.
05Already effective March 7, 2024 for federal employee plans only: Anterior and posterior cervical fusion, cervical discectomy and cervical laminectomy may be considered medically necessary when criteria are met under policy 7.01.560, and lumbar spinal fusion is considered investigational for chronic nonspecific low back pain without radiculopathy, degenerative disc disease, disc herniation, facet syndrome, and initial discectomy or laminectomy for neural structure decompression.
06Already effective March 7, 2024: Zynteglo criteria require that the individual does not have an uncorrected bleeding disorder or history of advanced liver disease, is 50 years of age or younger, and is clinically stable and eligible to undergo a hematopoietic stem cell transplant.

Codes mentioned

2056020561Q5123

Original notice

Medical Policy and Coding Updates - December 2023
premera.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account